
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is a clinical-stage biopharmaceutical company with a strong pipeline and solid financials, poised for success and growth. The company's lead candidate, pemvidutide, has the potential to address a significant unmet need in multiple liver diseases and has shown promise in early clinical trials. With a well-capitalized balance sheet and upcoming catalysts in the form of phase 2 and phase 3 trials, Altimmune is well-positioned for future success.
Bears say
Altimmune is facing multiple challenges as their drug pemvidutide faces further development and trials, and success in these trials is critical for the company's future success and stock performance. The company's near-term value-creation opportunity for pemvidutide may be limited, as there are other more advanced candidates in the market, and delays in development could harm the company's prospects. Additionally, the company may face competition from other drugs in the market and may need to form partnerships to complete clinical development and commercial launches, which could affect their profitability. Altimmune remains a buy due to its potential risk/reward opportunity, with its current low market valuation and upcoming catalysts including topline data from the Ph2 RECLAIM alcohol use disorder trial and the potential for a breakthrough therapy designation. However, the recent dilution and downgraded price target highlight concerns about potential further capital requirements and delays in trials.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares